[go: up one dir, main page]

WO1999009025A2 - Derives de 2-(4-aryl- ou heteroaryl-piperazin-1-ylmethyl)-1h-indole - Google Patents

Derives de 2-(4-aryl- ou heteroaryl-piperazin-1-ylmethyl)-1h-indole Download PDF

Info

Publication number
WO1999009025A2
WO1999009025A2 PCT/IB1998/001198 IB9801198W WO9909025A2 WO 1999009025 A2 WO1999009025 A2 WO 1999009025A2 IB 9801198 W IB9801198 W IB 9801198W WO 9909025 A2 WO9909025 A2 WO 9909025A2
Authority
WO
WIPO (PCT)
Prior art keywords
fluoro
disorders
piperazin
hydrogen
ylmethyl
Prior art date
Application number
PCT/IB1998/001198
Other languages
English (en)
Other versions
WO1999009025A3 (fr
Inventor
Anton Franz Josef Fliri
Mark Jerome Majchrzak
Patricia Ann Seymour
Stevin Howard Zorn
Hans Rollema
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to IL13396098A priority Critical patent/IL133960A0/xx
Priority to EP98935229A priority patent/EP1003739A2/fr
Priority to HU0003425A priority patent/HUP0003425A3/hu
Priority to AU84572/98A priority patent/AU8457298A/en
Priority to APAP/P/1998/001321A priority patent/AP9801321A0/en
Priority to CA002297486A priority patent/CA2297486C/fr
Priority to KR1020007001093A priority patent/KR20010022507A/ko
Priority to SK135-2000A priority patent/SK1352000A3/sk
Priority to PL98338947A priority patent/PL338947A1/xx
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Priority to BR9811557-0A priority patent/BR9811557A/pt
Priority to EA200000023A priority patent/EA200000023A1/ru
Priority to JP2000509706A priority patent/JP2002536291A/ja
Publication of WO1999009025A2 publication Critical patent/WO1999009025A2/fr
Publication of WO1999009025A3 publication Critical patent/WO1999009025A3/fr
Priority to BG104069A priority patent/BG104069A/xx
Priority to IS5336A priority patent/IS5336A/is
Priority to NO20000722A priority patent/NO20000722D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1 H- indole derivatives possessing central dopaminergic activity. Such compounds are useful in the treatment of Central Nervous Systems (CNS) disorders.
  • CNS Central Nervous Systems
  • This invention also relates to a method of using such compounds in the treatment of the above disorders in mammals, especially humans, and the pharmaceutical compositions useful therefor.
  • dopamine receptors seem to be important for many functions in the animal body. For example, altered functions of these receptors participate in the genesis of psychosis, drug addiction, compulsive disorders, bipolar disorders, vision, emesis, sleep, feeding, learning, memory, sexual behavior, regulation of immunological responses and blood pressure. Since these receptors control a great number of pharmacological events, not all of them are presently known, there is a possibility that compounds acting preferentially on D4 dopamine receptor may exert a wide range of therapeutic effects in humans.
  • the 2-(4-aryl or heteroaryi-piperazin-1-ylmethyl)-1H-indole derivatives of the present invention are centrally acting D4-dopamine receptor agonists and thus are useful as cognition enhancers and treatment of CNS diseases, such as Parkinsons disease, Alzheimer's disease, learning and memory abnormalities.
  • Another feature of this invention provides for the use of combinations " of compounds of the present invention in conjunction with D1 , D2, D3 or D5 dopamine receptor agonists, such as L- dopa and D2 agonists, in treatment of CNS diseases, such as Parkinson's disease, Alzheimer's disease, attention deficit disorder and learning and memory abnormalities.
  • a is 0 or 1 , wherein when a is 0, X may form an optional double bond with the carbon adjacent to V;
  • V is CHR 10 wherein R 10 is hydrogen or (d-C ⁇ alkyl; T is nitrogen or CH;
  • X is nitrogen or CR 11 wherein R 11 is hydrogen, (Ci-C ⁇ Jalkyl, (CrCeJalkoxy, hydroxy or cyano;
  • Y and Z are each independently nitrogen or CR 12 wherein R 12 is hydrogen, chloro, bromo, trifluoromethyi, trifluoromethoxy, cyano, (C-
  • R 1 is hydrogen, fluoro, chloro, bromo, trifluoromethyi, trifluoromethoxy, cyano or (C C 6 )alkyl; .
  • R 2 , R 6 , R 7 , R 8 and R 9 are each independently selected from hydrogen, fluoro, chloro, bromo, trifluoromethyi, trifluoromethoxy, cyano, (C ⁇ C ⁇ Jalkoxy and (C C 6 )alkyl;
  • R 3 and R 4 are each independently hydrogen or (d-CeJalkyl
  • R 5 is hydrogen, (d-C ⁇ alkoxy, trifluoromethyi, cyano, (C C 6 )alkyl or R 13 CO- wherein R 13 is amino, ((C 1 -C 6 )alkyl) 2 amino, (C 1 -C 6 )alkyl, (C 6 - C 10 )aryl; or when a is 1 , R 1 and R 10 may be taken together with the carbons to which they are attached to form a compound of the formula wherein the broken lines represent optional bonds;
  • T, X, Y, Z, R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 are defined as above; b is 0 or 1 ;
  • a and B are each independently CH, CH 2 , oxygen, sulfur, NH or nitrogen; with the proviso that when X is nitrogen, the optional double bond between X and V does not exist; with the proviso that when b is 0, the optional double bond between A and B does not exist; and with the proviso that when b is 1 , A and B cannot both be oxygen or sulfur.
  • alkyl as used herein, unless otherwise indicated, includes saturated monovending hydrocarbon radicals having straight, branched or cyclic moieties or combinations thereof.
  • alkoxy includes O-alkyl groups wherein "alky! is defined above.
  • treating refers to reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term applies, or one or more symptoms of such disorders or condition.
  • treatment refers to the act of treating, as “treating” is defined immediately above.
  • disorders of the dopamine system refers to disorders the treatment of which can be effected or facilitated by altering (i.e., increasing or decreasing) dopamine mediated neurotransmission.
  • the compounds in accordance with the present invention being ligands for dopamine receptor subtypes, especially the dopamine D receptor, within the body, are accordingly of use in the treatment of disorders of the dopamine system.
  • the compound of formula I may have chiral centers and therefore exist in different enantiomeric forms.
  • This invention relates to all optical isomers and stereoisomers of the compounds of formula I and mixtures thereof.
  • Preferred compounds of formula I include those wherein X is nitrogen.
  • R 2 is hydrogen, fluoro or chloro.
  • R 3 , R 4 and R 5 are hydrogen.
  • More preferred compounds of formula I include those wherein X is nitrogen; Y and Z are each CR 13 wherein R 3 is hydrogen or fluoro; R 2 is hydrogen fluoro or chloro; R 3 , R 4 and R 5 are hydrogen; R 7 is fluoro or chloro; and R 9 is fluoro, chloro, bromo or alkoxy.
  • Specific preferred compounds of formula I include the following:
  • the present invention also relates to a method for treating disorders of the dopamine system including psychotic disorders (affective psychosis, schizophrenia, and schizoaffective disorders), movement disorders (extrapyramidal side effects from neuroleptic agents, neuroleptic malignant syndrome, tardive dyskinesia, Gilles De La Tourette's syndrome, Parkinson's disease or Huntington's disease), gastrointestinal disorders (gastric acid secretion or emesis), chemical abuse, chemical dependencies, substance abuse, vascular and cardiovascular disorders (congestive heart failure and hypertension), ocular disorders and sleep disorders in a mammal, comprising administering to said mammal an amount of a D4 dopamine receptor selective compound according to formula I, or a pharmaceutically acceptable salt thereof, that is effective in treating such disorder.
  • psychotic disorders adjective psychosis, schizophrenia, and schizoaffective disorders
  • movement disorders extrapyramidal side effects from neuroleptic agents, neuroleptic malignant syndrome, tardive dyskinesia, Gilles De La Tourette'
  • the present invention also relates to a method for treating disorders of the dopamine system including psychotic disorders (affective psychosis, schizophrenia, and schizoaffective disorders), movement disorders (extrapyramidal side effects from neuroleptic agents, neuroleptic malignant syndrome, tardive dyskinesia, Gilles De La Tourette's syndrome, Parkinson's disease or Huntington's disease), gastrointestinal disorders (gastric acid secretion or emesis), chemical abuse, chemical dependencies, substance abuse, vascular and cardiovascular disorders (congestive heart failure and hypertension), ocular disorders and sleep disorders in a mammal, comprising administering to said mammal an amount of a D4 dopamine receptor selective compound according to formula I, or a pharmaceutically acceptable salt thereof, in conjunction with one or more D1, D2, D3 or D5 dopamine receptor agonists, that is effective in treating such disorder.
  • psychotic disorders adjective psychosis, schizophrenia, and schizoaffective disorders
  • movement disorders extrapyramidal side effects from neuroleptic agents
  • the present invention also relates to a pharmaceutical composition for treating disorders of the dopamine system including psychotic disorders (affective psychosis, schizophrenia, and schizoaffective disorders), movement disorders (extrapyramidal side effects from neuroleptic agents, neuroleptic malignant syndrome, tardive dyskinesia, Gilles De La Tourette's syndrome, Parkinson's disease or Huntington's disease), gastrointestinal disorders (gastric acid secretion or emesis), chemical abuse, chemical dependencies, substance abuse, vascular and cardiovascular disorders (congestive heart failure and hypertension), ocular disorders and sleep disorders in a mammal, comprising administering to said mammal an amount of a D4 dopamine receptor selective compound according to formula I, or a pharmaceutically acceptable salt thereof, that is effective in treating such disorder.
  • psychotic disorders adjective psychosis, schizophrenia, and schizoaffective disorders
  • movement disorders extrapyramidal side effects from neuroleptic agents, neuroleptic malignant syndrome, tardive dyskinesia, Gilles De La Tourette
  • the present invention also relates to a pharmaceutical composition for treating disorders of the dopamine system including psychotic disorders (affective psychosis, schizophrenia, and schizoaffective disorders), movement disorders (extrapyramidal side effects from neuroleptic agents, neuroleptic malignant syndrome, tardive dyskinesia, Gilles De La Tourette's syndrome, Parkinson's disease or Huntington's disease), gastrointestinal disorders (gastric acid secretion or emesis), chemical abuse, chemical dependencies, substance abuse, vascular and cardiovascular disorders (congestive heart failure and hypertension), ocular disorders and sleep disorders in a mammal, comprising administering to said mammal an amount of a D4 dopamine receptor selective compound according to formula I, or a pharmaceutically acceptable salt thereof, in conjunction with one or more D1, D2, D3 or D5 dopamine receptor agonists, that is effective in treating such disorder.
  • psychotic disorders adjective psychosis, schizophrenia, and schizoaffective disorders
  • movement disorders extrapyramidal side effects from neuroleptic
  • reaction 1 of Scheme 1 the compounds of formula III and IV are coupled to form the corresponding compound of formula I by first treating III with O-, N- dimethyl hydroxylamine hydrochloride, dicyciohexylcarbodiimide and a base, such as triethylamine, in a polar aprotic solvent, such as methylene chloride.
  • a polar aprotic solvent such as methylene chloride.
  • the hydroxamide intermediate so formed is reduced, using a reducing agent such as lithium aluminum hydride, in a polar aprotic solvent, such as tetrahydrofuran.
  • the reductive amination of the aldehyde intermediate so formed is accomplished by reacting the aldehyde with the compound of the formula IV in the presence of sodium triacetoxyborohydride and a polar aprotic solvent, such as dichloroethane.
  • the reaction mixture is stirred, under inert atmosphere, at room temperature for a time period between about 40 hours to about 56 hours, preferably about 48 hours.
  • the methanone compound of formula V is converted to the corresponding compound of formula I, wherein R 3 and R 4 are hydrogen, by reducing V with a reducing agent, such as lithium aluminum hydride or a borane derivative, in the presence of a polar aprotic solvent, such as tetrahydrofuran, for a time period between about 10 hours to about 14 hours, preferably about 12 hours.
  • a reducing agent such as lithium aluminum hydride or a borane derivative
  • a polar aprotic solvent such as tetrahydrofuran
  • pressure is not critical. Pressures in th range of about 0.5 atmospheres to 3 atmospheres are suitable, and ambient pressure (generally, about one atmosphere) is preferred as a matter of convenience. Also, for those reactions where the preferred temperature varies with the particular compounds reacted, no preferred temperature is stated. For such reactions, preferred temperatures for particular reactants may be determined by monitoring the reaction using thin layer chromatography.
  • novel compounds of the formula I and the pharmaceutically acceptable salts thereof are useful as dopaminergic agents, i.e., they possess the ability to alter dopamine mediated neurotransmission in mammals, including humans. They are therefore able to function as therapeutic agents in the treatment of a variety of conditions in mammals, the treatment or prevention of which can be effected or facilitated by an increase or decrease in dopamine mediated neurotransmission.
  • the compounds of the formula I that are basic in nature are capable of forming a wide variety of different salts with various inorganic and organic acids. Although such salts must be pharmaceutically acceptable for administration to animals, it is often desirable in practice to initially isolate a compound of the formula I from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert the latter back to the free base compound by treatment with an alkaline reagent and subsequently convert the latter free base to a pharmaceutically acceptable acid addition salt.
  • the acid addition salts of the base compounds of this invention are readily prepared by treating the base compound with a substantially equivalent amount of the chosen mineral or organic acid in an aqueous solvent medium or in a suitable organic solvent, such as methanol or ethanol. Upon careful evaporation of the solvent, the desired solid salt is readily obtained.
  • the desired acid salt can also be precipitated from a solution of the free base in an organic solvent by adding to the solution an appropriate mineral or organic acid.
  • the therapeutic compounds of this invention can be administered orally, transdermally (e.g. through the use of a patch), parenterally or topically. Oral administration is preferred. In general, these compounds are most desirably administered in dosages ranging from about 0.1 mg up to about 1000 mg per day, or 1 mg to 1000 mg per day in some cases, although variations may occur depending on the weight and condition of the person being treated and the particular route of administration chosen. In some instances, dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effect, provided that such larger doses are first divided into several small doses for administration throughout the day.
  • the therapeutic compounds of the invention may be administered alone or in combination with pharmaceutically acceptable earners or diluents by either of the two routes previously indicated, and such administration may be carried out in single or multiple doses. More particularly, the novel therapeutic compounds of this invention can be administered in a wide variety of different dosage forms, i.e., they may be combined with various pharmaceutically acceptable inert carriers in the form of tablets, capsules, lozenges, troches, hard candies, powders, sprays, creams, salves, suppositories, jellies, gels, pastes, lotions, ointments, elixirs, syrups, and the like. Such carriers include solid diluents or fillers, sterile aqueous media and various non-toxic organic solvents, for example. Moreover, oral pharmaceutical compositions can be suitably sweetened and/or flavored.
  • tablets containing various excipients such as microcrystalline cellulose, sodium citrate, calcium carbonate, dicalcium phosphate and glycine may be employed along with various disintegrants such as starch (and preferably corn, potato or tapioca starch), alginic acid and certain complex silicates, together with granulation binders like polyvinylpyrrolidone, sucrose, gelatin and acacia.
  • disintegrants such as starch (and preferably corn, potato or tapioca starch), alginic acid and certain complex silicates, together with granulation binders like polyvinylpyrrolidone, sucrose, gelatin and acacia.
  • lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tabletting purposes.
  • compositions of a similar type may also be employed as fillers in gelatin capsules; preferred materials in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols.
  • the active ingredient may be combined with various sweetening or flavoring agents, coloring matter or dyes, and, if so desired, emulsifying and/or suspending agents as well, together with such diluents as water, ethanol, propylene glycol, glycerin and various like combinations thereof.
  • solutions of a compound of the present invention in either sesame or peanut oil or in aqueous propylene glycol may be employed.
  • aqueous solutions should be suitably buffered if necessary and the liquid diluent first rendered isotonic. These aqueous solutions are suitable for intravenous injection purposes.
  • the oily solutions are suitable for intra-articuiar, intramuscular and subcutaneous injection purposes.
  • the preparation of all these solutions under sterile conditions is readily accomplished by standard pharmaceutical techniques well known to those skilled in the art. Additionally, it is also possible to administer the compounds of the present invention topically when treating inflammatory conditions of the skin and this may preferably be done by way of creams, jellies, gels, pastes, ointments and the like, in accordance with standard pharmaceutical practice.
  • D Receptor Binding Ability The determination of D 4 receptor binding ability has been described by Van Tol, et al. (Nature, 1991, 350, 610). Clonal cell lines expressing the human dopamine D 4 receptor are harvested and homogenized (polytron) in a 50 mM Tris:HCI (pH 7.4 at 4 °C) buffer containing 5 mM EDTA, 1.5 mM calcium chloride (CaCI 2 ), 5 mM magnesium chloride (MgCI 2 ), 5 mM potassium chloride (KCI) and 120 mM sodium chloride (NaCI). The homogenates are centrifugated for 10-15 min.
  • tissue homogenate is incubated in triplicate with increasing concentrations of (70.3 Ci/mmol; 10-3000 pM final concentration) for 30- 120 minutes at 22 °C in a total volume of 1 ml.
  • assays are initiated by the addition of 0.75 ml of membrane and incubated in duplicate with the indicated concentrations of competing ligands (10 "14 -10 "3 M) and/or [ 3 H]- spiperone (100-300 pM) for 60-120 min at 22°C.
  • CHO cells expressing the human D4.4 dopamine receptor were obtained from Dr. H. Van Tol (Clarke Institute of Psychiatry, Toronto), and were grown to confluence in Minimal Essential Alpha Media (Gibco) supplemented with 2.5% Fetal Bovine Serum (not heat inactivated), 2.5% Equine Serum (heat inactivated), and 500 ⁇ g/ml Geneticin.
  • Monolayers were disrupted and cells disloged with 5 mM ethylenediaminetetraacetic acid (EDTA) and resuspended in phosphate buffered saline buffer containing 5 mM magnesium chloride, 30 mM hydroxyethylpiperazine-N-ethanesulfonic acid (HEPES), 300 ⁇ M 3-isobutyl-1-methyl- xanthine (IBMX, a phosphodiesterase inhibitor), and 5.6 mM dextrose.
  • EDTA ethylenediaminetetraacetic acid
  • HEPES hydroxyethylpiperazine-N-ethanesulfonic acid
  • IBMX 3-isobutyl-1-methyl- xanthine
  • EXAMPLE 2 5-Fluoro-1 H-indol-2-yl)-[4-(3-trifluoromethyl-phenyl)-piperazin-1-yl1-methanone A mixture of 1.0 mmol of 5-fluoro, 2-indole carboxylicacidchloride and 230 mg of meta-trifiuoromethylphenylpiperazine and 129 mg of diisopropylethylamine in 10 ml methylenchloride is kept at ambient temperature for 12 hours. Water is added, the organic layers separated, washed with wate, dried over sodium sulfate and concentrated to yield 296 mg of the title compound. MP: 198°C. EXAMPLE 3
  • -1 H-indole hydrochloride A solution of 275 mg of 5-Fluoro-1 H-indol-2-yl)-[4-(3-trifluoromethyl-phenyl)- piperazin-1-yl]methanone in 5 ml anhydrous tetrahydrofurane is kept under an inert gas atmosphere and is treated at ambient temperature with 2.11 ml of a 1M solution of Lithiumaluminumhydride in tetrahydrofurane.
  • EXAMPLE 42 (2' ⁇ . 3'a ⁇ . 5' ⁇ . 6'a ⁇ V2-Fluoro-4-r4-(3. 3'. 3'a. 4. 4'. 5'. 6'. a-hexahydrospiropH- 1 -benzopyran-2.2'(1 'W-oentalen]- 5'-yh-1 -piperazinyl]-benzonitrile maleate
  • EXAMPLE 52 (2' ⁇ . 3'a ⁇ . 5' ⁇ . 6'a ⁇ -Phenyl-4-(3. 3'. 3'a. 4. 4'. 5'. 6'. 6'a-hexahvdrospiro[2H-1- benzopyran-2.2'(1 ⁇ pentaleny5'-vl -5'-vlVpiperazine maleate
  • EXAMPLE 53 (2' ⁇ . 3'a ⁇ . 5' ⁇ . 6'a ⁇ 1-Phenyl-4-(3. 3'. 3'a. 4. 4'. 5'. 6'. 6'a-hexahvdrospiro H-1- benzopyran-2.2'(1 ⁇ Vpentalen]-5'-yl]-5'-yl)-piperazine maleate
  • EXAMPLE 54 (2' ⁇ . 3'a ⁇ . 5' ⁇ . 6'a ⁇ 3-f5'-(4-Phenvl-piperazin-1-vn- octahvdro-pentalen-2'-yl]- 1 H-indole maleate
  • EXAMPLE 56 (2' ⁇ . 3'a ⁇ . 5' ⁇ . 6'a ⁇ V1-Phenyl-4-(5'-phenyl-octahvdro-pentalen-2'-vn-piperazine maleate
  • EXAMPLE 77 (2' ⁇ . 3'a ⁇ . 5' ⁇ . 6'aB)-5-Fluoro-2-r4-(3'. 3'a. 4'. 5'. 6'. 6'a-hexahvdro-3'a fi'a- dimethylspiropsobenzofuran-1 (3H 2'(1 'H)-pentalen -5'-vh-1 -piperazinyl]-pyrimidine maleate MP: 222-223°C. NMR DMSO d 6 ⁇ 8.58 (s, 2H), 7.34-7.30 (m, 1H), 7.28-7.25 (m,

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne un composé correspondant à la formule (I) dans laquelle a, T, V, X, Y, Z, R?1, R2, R3, R4, R5, R6, R7, R8 et R9¿ possèdent les notations données dans la description. Elle concerne également des sels de ce composé, acceptables sur le plan pharmacologique, ainsi que des compositions pharmaceutiques contenant de tels composés ou sels.
PCT/IB1998/001198 1997-08-15 1998-08-05 Derives de 2-(4-aryl- ou heteroaryl-piperazin-1-ylmethyl)-1h-indole WO1999009025A2 (fr)

Priority Applications (15)

Application Number Priority Date Filing Date Title
PL98338947A PL338947A1 (en) 1997-08-15 1998-08-05 Derivatives of 2-(4-aryl or heteroaryl piperazin-1-ylmethyl)-1h-indole
HU0003425A HUP0003425A3 (en) 1997-08-15 1998-08-05 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1h-indole derivatives and pharmaceutical compositions containing the compounds
AU84572/98A AU8457298A (en) 1997-08-15 1998-08-05 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1H-indole derivatives interacting with the dopamine D4 receptor
APAP/P/1998/001321A AP9801321A0 (en) 1997-08-15 1998-08-05 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-h-indole derivatives.
CA002297486A CA2297486C (fr) 1997-08-15 1998-08-05 Derives de 2-(4-aryl- ou heteroaryl-piperazin-1-ylmethyl)-1h-indole
KR1020007001093A KR20010022507A (ko) 1997-08-15 1998-08-05 도파민 디4 수용체와 상호작용하는 2-(4-아릴 또는헤테로아릴-피페라진-1-일메틸)-1수소-인돌 유도체
SK135-2000A SK1352000A3 (en) 1997-08-15 1998-08-05 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1h-indole derivatives interacting with the dopamine d4 receptor
IL13396098A IL133960A0 (en) 1997-08-15 1998-08-05 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1h-indole derivatives
BR9811557-0A BR9811557A (pt) 1997-08-15 1998-08-05 Derivados do 2-)4-aril ou heteroaril-piperazin-1-ilmetil)-1h-indol
EP98935229A EP1003739A2 (fr) 1997-08-15 1998-08-05 Derives de 2-(4-aryl- ou heteroaryl-piperazin-1-ylmethyl)-1h-indole
EA200000023A EA200000023A1 (ru) 1997-08-15 1998-08-05 Производные 2-(-4-арил или гетероарил-пиперазин-1-илметил) -1h-индола
JP2000509706A JP2002536291A (ja) 1997-08-15 1998-08-05 ２−（４−アリール又はヘテロアリール−ピペラジン−１−イルメチル）−１ｈ−インドール誘導体
BG104069A BG104069A (en) 1997-08-15 2000-01-10 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1h-indole derivatives interacting with the dopamine d4 receptor
IS5336A IS5336A (is) 1997-08-15 2000-01-11 2-(4-Arýl eða heteróarýl-píperazín-1-ýlmetýl)-1H-indól afleiður
NO20000722A NO20000722D0 (no) 1997-08-15 2000-02-14 2-(4-aryl eller heteroaryl-piperazin-1-ylmetyl)-1H- indolderivater

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5576497P 1997-08-15 1997-08-15
US60/055,764 1997-08-15

Publications (2)

Publication Number Publication Date
WO1999009025A2 true WO1999009025A2 (fr) 1999-02-25
WO1999009025A3 WO1999009025A3 (fr) 1999-04-15

Family

ID=22000003

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB1998/001198 WO1999009025A2 (fr) 1997-08-15 1998-08-05 Derives de 2-(4-aryl- ou heteroaryl-piperazin-1-ylmethyl)-1h-indole

Country Status (30)

Country Link
EP (1) EP1003739A2 (fr)
JP (1) JP2002536291A (fr)
KR (1) KR20010022507A (fr)
CN (1) CN1265660A (fr)
AP (1) AP9801321A0 (fr)
AR (1) AR017019A1 (fr)
AU (1) AU8457298A (fr)
BG (1) BG104069A (fr)
BR (1) BR9811557A (fr)
CA (1) CA2297486C (fr)
CO (1) CO4960656A1 (fr)
DZ (1) DZ2583A1 (fr)
EA (1) EA200000023A1 (fr)
HR (1) HRP980441A2 (fr)
HU (1) HUP0003425A3 (fr)
ID (1) ID23803A (fr)
IL (1) IL133960A0 (fr)
IS (1) IS5336A (fr)
MA (1) MA24632A1 (fr)
NO (1) NO20000722D0 (fr)
OA (1) OA11286A (fr)
PA (1) PA8457001A1 (fr)
PE (1) PE106299A1 (fr)
PL (1) PL338947A1 (fr)
SK (1) SK1352000A3 (fr)
TN (1) TNSN98151A1 (fr)
TR (1) TR200000414T2 (fr)
UY (1) UY25144A1 (fr)
WO (1) WO1999009025A2 (fr)
ZA (1) ZA987304B (fr)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0953567A2 (fr) * 1998-04-29 1999-11-03 Pfizer Products Inc. Dérivés de piperazin-, piperidine- et tetrahydropyridine bicyclique substitués, leur préparation et leur utilisation comme agents a activité dopaminergique (recepteur D4 de la dopamine) centrale
WO2001049679A1 (fr) * 1999-12-30 2001-07-12 H. Lundbeck A/S Derives de 4-phenyle-1-piperazinyle, -piperidinyle et -tetrahydropyridyle
WO2002007766A3 (fr) * 2000-07-22 2002-07-18 Univ Manchester Traitement de la dyskinesie
WO2002072548A3 (fr) * 2001-03-09 2002-12-12 Ortho Mcneil Pharm Inc Composes heterocycliques
US6548502B2 (en) 2000-07-27 2003-04-15 Pfizer Inc Dopamine D4 ligands for the treatment of novelty-seeking disorders
WO2004108671A1 (fr) * 2003-06-06 2004-12-16 Suven Life Sciences Limited Indoles substitues dotes d'une affinite pour le recepteur de la serotonine, leur procede de fabrication et compositions pharmaceutiques les contenant
WO2007048779A1 (fr) * 2005-10-26 2007-05-03 Janssen Pharmaceutica N.V. Dérivés de pipéridin-4-yl-pyridazin-3-ylamine en tant qu'antagonistes à dissociation rapide du récepteur 2 de la dopamine
WO2008098892A1 (fr) * 2007-02-13 2008-08-21 Janssen Pharmaceutica N.V. Antagonistes du récepteur de la dopamine 2 se dissociant rapidement
US7504426B2 (en) 2002-09-06 2009-03-17 Janssen Pharmaceutica N.V. Heterocyclic compounds
US7572805B2 (en) 2004-07-14 2009-08-11 Bristol-Myers Squibb Company Pyrrolo(oxo)isoquinolines as 5HT ligands
US7618980B2 (en) 2004-07-14 2009-11-17 Bristol-Myers Squibb Company Pyrrolo(oxo)quinolines as 5HT ligands
EP2253315A1 (fr) 2004-03-30 2010-11-24 Takeda Pharmaceutical Company Limited Dérivés d'acide alkoxypropanoique
US8466153B2 (en) 2006-12-08 2013-06-18 Janssen Pharmaceutica N.V. Piperidinylamino-pyridazines and their use as fast dissociating dopamine 2 receptor antagonists
US8530474B2 (en) 2008-07-03 2013-09-10 Janssen Pharmaceutica Nv Substituted 6-(1-piperazinyl)-pyridazines as 5-HT6 receptor antagonists
US8895562B2 (en) 2008-07-31 2014-11-25 Janssen Pharmaceutica Nv Piperazin-1-yl-trifluoromethyl-substituted-pyridines as fast dissociating dopamine 2 receptor antagonists
US8906921B2 (en) 2007-04-23 2014-12-09 Janssen Pharmaceutica Nv 4-alkoxypyridazine derivatives as fast dissociating dopamine 2 receptor antagonists
US8933101B2 (en) 2007-04-23 2015-01-13 Janssen Pharmaceutica Nv Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists
EP3686196A4 (fr) * 2017-09-20 2021-03-31 Hangzhou Innogate Pharma Co., Ltd. Composé polycyclique agissant en tant qu'inhibiteur de l'ido et/ou en tant qu'inhibiteur double de l'ido-hdac
EP4139291A4 (fr) * 2020-04-22 2024-05-29 Anima Biotech Inc. Inhibiteurs de traduction de collagène 1 et leurs procédés d'utilisation

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1027336T3 (da) * 1997-10-27 2005-01-24 Neurosearch As Heteroaryldiazacycloalkaner, deres fremstilling og anvendelse

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB944443A (fr) * 1959-09-25 1900-01-01
DK0594702T3 (da) * 1991-07-03 1997-07-21 Upjohn Co Substituerede indoler som midler mod AIDS
JPH05255089A (ja) * 1991-12-18 1993-10-05 Sanwa Kagaku Kenkyusho Co Ltd 抗ウイルス剤
EP0665840A1 (fr) * 1992-10-23 1995-08-09 MERCK SHARP & DOHME LTD. Ligands pour les sous-types de recepteurs de dopamine
GB9305644D0 (en) * 1993-03-18 1993-05-05 Merck Sharp & Dohme Therapeutic agents
US5576336A (en) * 1993-03-18 1996-11-19 Merck Sharp & Dohme Limited Indole derivatives as dopamine D4 antagonists
US5814644A (en) * 1993-04-15 1998-09-29 Merck Sharp & Dohme, Ltd. Indole derivatives as dopamine D4 antagonists
DE4414113A1 (de) * 1994-04-22 1995-10-26 Merck Patent Gmbh 3-Indolylpiperidine
TW406075B (en) * 1994-12-13 2000-09-21 Upjohn Co Alkyl substituted piperidinyl and piperazinyl anti-AIDS compounds
ZA968661B (en) * 1995-11-17 1998-04-14 Upjohn Co Oxazolidinone antibacterial agent with tricyclic substituents.
TW504510B (en) * 1996-05-10 2002-10-01 Janssen Pharmaceutica Nv 2,4-diaminopyrimidine derivatives

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372762B1 (en) 1998-04-29 2002-04-16 Pfizer Inc. Substituted bicyclic derivatives for treating central nervous system disorders
EP0953567A2 (fr) * 1998-04-29 1999-11-03 Pfizer Products Inc. Dérivés de piperazin-, piperidine- et tetrahydropyridine bicyclique substitués, leur préparation et leur utilisation comme agents a activité dopaminergique (recepteur D4 de la dopamine) centrale
US7074796B2 (en) 1999-12-30 2006-07-11 H. Lundbeck A/S 4-phenyl-1-piperazinyl, -piperidinyl and -tetrahydropyridyl derivatives
WO2001049679A1 (fr) * 1999-12-30 2001-07-12 H. Lundbeck A/S Derives de 4-phenyle-1-piperazinyle, -piperidinyle et -tetrahydropyridyle
EA008627B1 (ru) * 1999-12-30 2007-06-29 Х. Лундбекк А/С Замещенные галогеном производные 4-фенил-1-пиперазинила, их применение и содержащая их фармацевтическая композиция
US7223765B2 (en) 1999-12-30 2007-05-29 H. Lundbeck A/S 4-phenyl-1-piperazinyl, -piperidinyl and -tetrahydropyridyl derivatives
WO2002007766A3 (fr) * 2000-07-22 2002-07-18 Univ Manchester Traitement de la dyskinesie
US6548502B2 (en) 2000-07-27 2003-04-15 Pfizer Inc Dopamine D4 ligands for the treatment of novelty-seeking disorders
WO2002072548A3 (fr) * 2001-03-09 2002-12-12 Ortho Mcneil Pharm Inc Composes heterocycliques
US6803362B2 (en) 2001-03-09 2004-10-12 Ortho-Mcneil Pharmaceutical Inc. Heterocyclic compounds
JP2004520434A (ja) * 2001-03-09 2004-07-08 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 複素環化合物
US7504426B2 (en) 2002-09-06 2009-03-17 Janssen Pharmaceutica N.V. Heterocyclic compounds
WO2004108671A1 (fr) * 2003-06-06 2004-12-16 Suven Life Sciences Limited Indoles substitues dotes d'une affinite pour le recepteur de la serotonine, leur procede de fabrication et compositions pharmaceutiques les contenant
EP2253315A1 (fr) 2004-03-30 2010-11-24 Takeda Pharmaceutical Company Limited Dérivés d'acide alkoxypropanoique
US7618980B2 (en) 2004-07-14 2009-11-17 Bristol-Myers Squibb Company Pyrrolo(oxo)quinolines as 5HT ligands
US7572805B2 (en) 2004-07-14 2009-08-11 Bristol-Myers Squibb Company Pyrrolo(oxo)isoquinolines as 5HT ligands
AU2006307930B2 (en) * 2005-10-26 2011-10-06 Janssen Pharmaceutica N.V. Piperidin-4-YL-pyridazin-3-YLamine derivatives as fast dissociating dopamine 2 receptor antagonists
KR101351910B1 (ko) 2005-10-26 2014-01-16 얀센 파마슈티카 엔.브이. 빠르게 해리하는 도파민 ２ 수용체 길항제로서의피페리딘―４―일―피리다진―３―일아민 유도체
WO2007048779A1 (fr) * 2005-10-26 2007-05-03 Janssen Pharmaceutica N.V. Dérivés de pipéridin-4-yl-pyridazin-3-ylamine en tant qu'antagonistes à dissociation rapide du récepteur 2 de la dopamine
EA015681B1 (ru) * 2005-10-26 2011-10-31 Янссен Фармацевтика Н.В. Производные пипередин-4-ил-пиридазин-3-иламина как быстро диссоциирующие антагонисты рецептора дофамина 2
US9751860B2 (en) 2005-10-26 2017-09-05 Janssen Pharmaceutica Nv Piperidin-4YL-pyridazin-3-ylamine derivatives as fast dissociating dopamine 2 receptor antagonists
AP2607A (en) * 2005-10-26 2013-03-05 Janssen Pharmaceutica Nv Piperidin-4-yl-pyridazin-3-ylamine derivatives as fast dissociating dopamine 2 receptor antagonists
US9468640B2 (en) 2005-10-26 2016-10-18 Janssen Pharmaceutica Nv Piperidin-4-yl-pyridazin-3-ylamine derivatives as fast dissociating dopamine 2 receptor antagonists
TWI399373B (zh) * 2005-10-26 2013-06-21 Janssen Pharmaceutica Nv 快速解離之多巴胺２受體拮抗劑
US8940743B2 (en) 2005-10-26 2015-01-27 Janssen Pharmaceutica Nv Piperidin-4-yl-pyridazin-3-ylamine derivatives as fast dissociating dopamine 2 receptor antagonists
US8466153B2 (en) 2006-12-08 2013-06-18 Janssen Pharmaceutica N.V. Piperidinylamino-pyridazines and their use as fast dissociating dopamine 2 receptor antagonists
AU2008214716B2 (en) * 2007-02-13 2013-05-09 Janssen Pharmaceutica N.V. Fast dissociating dopamine 2 receptor antagonists
TWI424847B (zh) * 2007-02-13 2014-02-01 Janssen Pharmaceutica Nv 快速解離之多巴胺２受體拮抗劑
US8791120B2 (en) 2007-02-13 2014-07-29 Janssen Pharmaceutica Nv Fast-dissociating dopamine 2 receptor antagonists
US9422296B2 (en) 2007-02-13 2016-08-23 Janssen Pharmaceutica Nv Fast-dissociating dopamine 2 receptor antagonists
WO2008098892A1 (fr) * 2007-02-13 2008-08-21 Janssen Pharmaceutica N.V. Antagonistes du récepteur de la dopamine 2 se dissociant rapidement
EA017508B1 (ru) * 2007-02-13 2013-01-30 Янссен Фармацевтика Н.В. Быстро диссоциирующие антагонисты рецептора 2 дофамина
US8906921B2 (en) 2007-04-23 2014-12-09 Janssen Pharmaceutica Nv 4-alkoxypyridazine derivatives as fast dissociating dopamine 2 receptor antagonists
US8933101B2 (en) 2007-04-23 2015-01-13 Janssen Pharmaceutica Nv Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists
US8530474B2 (en) 2008-07-03 2013-09-10 Janssen Pharmaceutica Nv Substituted 6-(1-piperazinyl)-pyridazines as 5-HT6 receptor antagonists
US8895562B2 (en) 2008-07-31 2014-11-25 Janssen Pharmaceutica Nv Piperazin-1-yl-trifluoromethyl-substituted-pyridines as fast dissociating dopamine 2 receptor antagonists
EP3686196A4 (fr) * 2017-09-20 2021-03-31 Hangzhou Innogate Pharma Co., Ltd. Composé polycyclique agissant en tant qu'inhibiteur de l'ido et/ou en tant qu'inhibiteur double de l'ido-hdac
EP4139291A4 (fr) * 2020-04-22 2024-05-29 Anima Biotech Inc. Inhibiteurs de traduction de collagène 1 et leurs procédés d'utilisation

Also Published As

Publication number Publication date
JP2002536291A (ja) 2002-10-29
HUP0003425A3 (en) 2002-02-28
AR017019A1 (es) 2001-08-22
PA8457001A1 (es) 2000-09-29
CA2297486A1 (fr) 1999-02-25
BG104069A (en) 2001-05-31
CN1265660A (zh) 2000-09-06
OA11286A (en) 2003-10-22
DZ2583A1 (fr) 2003-02-22
NO20000722L (no) 2000-02-14
PL338947A1 (en) 2000-12-04
MA24632A1 (fr) 1999-04-01
AU8457298A (en) 1999-03-08
NO20000722D0 (no) 2000-02-14
PE106299A1 (es) 1999-11-02
KR20010022507A (ko) 2001-03-15
ZA987304B (en) 2000-02-14
UY25144A1 (es) 2000-12-29
TNSN98151A1 (fr) 2005-03-15
IL133960A0 (en) 2001-04-30
IS5336A (is) 2000-01-11
EP1003739A2 (fr) 2000-05-31
WO1999009025A3 (fr) 1999-04-15
HRP980441A2 (en) 1999-04-30
SK1352000A3 (en) 2000-08-14
ID23803A (id) 2000-05-11
CA2297486C (fr) 2005-05-03
CO4960656A1 (es) 2000-09-25
TR200000414T2 (tr) 2000-08-21
HUP0003425A2 (hu) 2001-10-28
BR9811557A (pt) 2000-08-22
EA200000023A1 (ru) 2000-08-28
AP9801321A0 (en) 2000-02-14

Similar Documents

Publication Publication Date Title
WO1999009025A2 (fr) Derives de 2-(4-aryl- ou heteroaryl-piperazin-1-ylmethyl)-1h-indole
KR101463572B1 (ko) Ｎｏｓ 저해 활성을 갖는 치환된 인돌 화합물
US6608084B1 (en) Aza-bicycles which modulate the inhibition of cell adhesion
US5834493A (en) Indole derivatives as 5-HT1A and/or 5-HT2 ligands
AU765317B2 (en) 4,5,6 and 7-indole and indoline derivatives, their preparation and use
MXPA02007318A (es) Pirrolidinas 1,3-disubstituidas como antagonistas del adrenoceptor alfa-2.
JP2006502181A (ja) ５−ｈｔ４レセプターアゴニストとしてのイミダゾピリジン化合物
Andersen et al. Selective, centrally acting serotonin 5-HT2 antagonists. 2. Substituted 3-(4-fluorophenyl)-1H-indoles
JP3004727B2 (ja) ドパミン作動性活性を有するベンゾイミダゾール誘導体
CA2472470A1 (fr) Ligands recepteurs de l'hormone de concentration de la melanine: analogues de benzoimidazole substitue
EP1581522B1 (fr) Derives de flavaxate comme antagonistes de recepteurs muscariniques
WO2008147945A1 (fr) Dérivés d'azacyclylbenzamide en tant qu'antagonistes de l'histamine-3
CN101910126B (zh) 作为大麻素受体之配体的脯氨酸类似物
US4659731A (en) 2-(4,5-Dihydro-1H-imidazol-2-yl)-2,3-dihydroindole derivatives and their application as α2 receptor antagonist or α1 receptor agonists
ES2210219T3 (es) Derivados de octahidro-2h-pirido- (1,2-a) -pirazina, su procedimiento de preparacion y las composiciones farmaceuticas que lo contienen.
CA2346896C (fr) 3-tetrahydropyridin-4-yl indoles pour le traitement des troubles psychotiques
CN112041300B (zh) 作为双重5-ht2a和5-ht6受体拮抗剂的吲哚和苯并咪唑衍生物
CA2330436A1 (fr) Derives d'indolyle utilises comme agents serotoninergiques
US20040198734A1 (en) 2-(4-Aryl or heteroaryl-piperazin-1-ylmethyl)-1H-indole derivatives interacting with the dopamine
SK19412000A3 (sk) Substituované 4,5,6 a 7-indolové alebo indolínové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie
KR101471987B1 (ko) 일정한 ｃｎｓ-관련 질환을 치료하기 위한 2-알킬-인다졸 화합물
MXPA00001611A (en) 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1h-indole derivatives
FR2773800A1 (fr) Derives de benzimidazole, leur procede de preparation et leur application en therapeutique
CZ2000307A3 (cs) Deriváty 2-(4-aryI nebo heteroarylpiperazin-1- ylmetyl)-lH-indolu
CA2327513A1 (fr) N-aryloxyethyle-indoly-alkylamines pour le traitement de la depression

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 133960

Country of ref document: IL

Ref document number: P-26/00

Country of ref document: YU

Ref document number: 98807831.7

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 84572/98

Country of ref document: AU

Ref document number: 502282

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2297486

Country of ref document: CA

Ref document number: 2297486

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 200000023

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: PV2000-307

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 1352000

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 1020007001093

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1998935229

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/001611

Country of ref document: MX

Ref document number: 2000/00414

Country of ref document: TR

WWP Wipo information: published in national office

Ref document number: 1998935229

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09423064

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: PV2000-307

Country of ref document: CZ

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020007001093

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: 1020007001093

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1998935229

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV2000-307

Country of ref document: CZ